Shares in BioVie (Nasdaq: BIVI) closed 61% lower on Wednesday.
The US neurology company had revealed efficacy data from the Phase III trial of NE3107 in mild to moderate Alzheimer's disease.
In the trial, the primary efficacy endpoint missed statistical significance, a fact blamed by BioVie on problems that arose during the study, rather than on the drug itself.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze